Quizartinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 392 publications
Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy.
Journal: Journal of managed care & specialty pharmacy
Published: July 27, 2026
Phlegmonous Gastritis During Consolidation Therapy With High-Dose Cytarabine and FLT3 Inhibitor in FLT3-ITD-Mutated Acute Myeloid Leukemia.
Journal: Cureus
Published: July 22, 2026
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
Journal: Future oncology (London, England)
Published: July 11, 2026
Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism.
Journal: Journal of medicinal chemistry
Published: June 18, 2026
Recent advances in the treatment of FLT3-mutated acute myeloid leukemia.
Journal: Blood research
Published: June 07, 2026
Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.
Journal: Journal of medicinal chemistry
Published: May 23, 2026
Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.
Journal: Blood cancer journal
Published: May 20, 2026
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.
Journal: American journal of hematology
Published: April 24, 2026
Predicting target interactomes and prognostic biomarkers of Quizartinib in acute myeloid leukemia: An integrative network pharmacology and In-silico approach.
Journal: Computational biology and chemistry
Published: April 10, 2026
Last Updated: 09/26/2026